Insider Buying Report: SAVA and BCDA
ByAinvest
Tuesday, Sep 23, 2025 10:47 am ET1min read
BCDA--
Cassava Sciences (SAVA)
Cassava Sciences shares are trading higher on Tuesday, with a 19.61% increase to $2.77. The stock has a 52-week high of $33.98 and a 52-week low of $1.15. The insider purchase by CEO Richard Barry is viewed as a vote of confidence in the company's future, following the recent halt in the development of its Alzheimer’s drug, simufilam, after the Phase 3 REFOCUS-ALZ trial failed to meet its primary endpoints [1].
BioCardia (BCDA)
BioCardia shares are also experiencing a rebound, up 11.7% on Tuesday to $1.25. The stock has a 52-week high of $1.63 and a 52-week low of $0.90. Director Simon H. Stertzer's purchase is seen as a positive signal, especially given the company's recent financial challenges and market pressures [2].
Both companies have faced significant market challenges, with Cassava Sciences' stock collapsing by over 91% in the past year due to the trial failure of simufilam, and BioCardia's stock falling 32.38% in the past week. The insider purchases are a sign of optimism among key executives and may indicate a potential turnaround for both companies.
References
[1] https://www.benzinga.com/trading-ideas/movers/25/09/47819841/cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
[2] https://www.investing.com/news/company-news/biocardia-prices-6-million-public-offering-of-common-stock-and-warrants-93CH-4245076
SAVA--
Two notable insider buys have been reported: Cassava Sciences (SAVA) CEO Richard Barry purchased 237,941 shares for $534,743, and BioCardia (BCDA) Director Simon H. Stertzer bought 398,400 shares for $498,000. Both purchases occurred on Friday and mark the first buy for Barry and the fourth buy for Stertzer in the past year. SAVA is up 19.8% and BCDA is up 11.7% on Tuesday.
Two significant insider buys have been reported this week, contributing to the upward movement of Cassava Sciences (SAVA) and BioCardia (BCDA) stocks. On Friday, Cassava Sciences CEO Richard Barry purchased 237,941 shares at an average price of $2.25 each, while BioCardia Director Simon H. Stertzer bought 398,400 shares at an average price of $1.25 each. Both purchases occurred on the same day and mark the first buy for Barry and the fourth buy for Stertzer in the past year.Cassava Sciences (SAVA)
Cassava Sciences shares are trading higher on Tuesday, with a 19.61% increase to $2.77. The stock has a 52-week high of $33.98 and a 52-week low of $1.15. The insider purchase by CEO Richard Barry is viewed as a vote of confidence in the company's future, following the recent halt in the development of its Alzheimer’s drug, simufilam, after the Phase 3 REFOCUS-ALZ trial failed to meet its primary endpoints [1].
BioCardia (BCDA)
BioCardia shares are also experiencing a rebound, up 11.7% on Tuesday to $1.25. The stock has a 52-week high of $1.63 and a 52-week low of $0.90. Director Simon H. Stertzer's purchase is seen as a positive signal, especially given the company's recent financial challenges and market pressures [2].
Both companies have faced significant market challenges, with Cassava Sciences' stock collapsing by over 91% in the past year due to the trial failure of simufilam, and BioCardia's stock falling 32.38% in the past week. The insider purchases are a sign of optimism among key executives and may indicate a potential turnaround for both companies.
References
[1] https://www.benzinga.com/trading-ideas/movers/25/09/47819841/cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
[2] https://www.investing.com/news/company-news/biocardia-prices-6-million-public-offering-of-common-stock-and-warrants-93CH-4245076
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet